LB Pharmaceuticals Inc Common Stock
$42.47
Market Cap
$1.36B
Shares Outstanding
32.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 11, 2025
Round Lot
100
Locale
US
Day Open
$42.22
Day High
$42.54
Day Low
$41.38
Volume
531.6K
VWAP
$42.12
Prev Close
$42.14
Transactions
--
Acc. Volume
--
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LB Pharmaceuticals Inc Common Stock (LBRX) closed the 2026-09-18 session at $42.47, up 0.78% versus the previous close (+0.33). The stock opened at $42.22 and traded between $41.38 and $42.54 during that session. Session trading volume was 532K shares. The volume-weighted average price (VWAP) is $42.12.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LB Pharmaceuticals Inc Common Stock has a market capitalization of $1.36 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. LBRX is listed on the XNAS exchange. The company employs approximately 27 people. LB Pharmaceuticals Inc Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2025-09-11.
On this page you can find market LBRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.